Search

everythinglearnresearchcommunity

for

Search:↓

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Topical human epidermal growth factor may effectively treat acne caused by cancer medication.

EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.

EGFR inhibitors can cause yellowish skin eruptions.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.

Doxycycline can effectively treat hair loss caused by EGFR inhibitors.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Lasers can help reduce skin side effects from cancer treatment.

Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.

Erlotinib can cause nonscarring hair loss and itchy skin.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Erlotinib may cause scarring hair loss.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

New cancer drugs often cause skin and nail problems.

Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.

Erlotinib can cause hair loss as a side effect.

Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Cancer treatments often cause skin, nail, and hair problems.

Chemotherapy often causes skin and hair issues, but early management can help improve patient care.